HIV and Inflammatory or Autoimmune Disease: Rare Patients, Many Questions (MAIVIH)

Hiv Clinical Trial

— MAIVIH  

Official title:

HIV and Inflammatory or Autoimmune Disease: Rare Patients, Many Questions (MAIVIH)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05036811
• Other study ID #: NRIPH_2020_11
• Status: Recruiting
• Start date: June 7, 2021
• Est. completion date: March 2023

Study information

• Verified date: April 2021
• Source: Tourcoing Hospital
• Contact: Nathalie VIGET, MD
• Phone: 0320694848
• Email: nviget[@]ch-tourcoing.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Follow-up registry of patients living with HIV who also have various inflammatory and autoimmune pathologies that may require immunosuppressive treatment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 400
• Est. completion date: March 2023
• Est. primary completion date: December 2022
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient living with HIV

• Carrier of one or more of the following diseases:

Sarcoidosis Multiple sclerosis Myasthenia gravis Crohn's disease Hemorrhagic rectocolitis Autoimmune hepatitis Arthropathic psoriasis Still's disease, other rheumatoid arthritides, juvenile polyarthritides, Rheumatoid arthritis Vasculitides: periarteritis nodosa and related conditions, other necrotizing vasculopathies (periarteritis nodosa, juvenile periarteritis, Churg-Strauss disease, polyangiitis, Kawasaki disease, Horton's disease, Wegener's disease, thrombotic microangiopathy, Takayashu syndrome, Good-Pasture's syndrome, thrombocytopenic purpura) Lupus Polymyositis or dermatopolymyositis Connectivitis (Behcet's disease, Gougerot-Sjöogren syndrome) Inflammatory spondyloarthropathies (APS, spondyloarthritis, other spondyloarthropathies)

Exclusion Criteria:

• Opposition of the person

• Minor patients

• Patients under judicial protection

Related Conditions & MeSH terms

• Autoimmune Diseases
• Hiv

Intervention

Other:
• data collection
data collection

Locations

Country	Name	City	State
France	CH Tourcoing	Tourcoing

Sponsors (1)

Lead Sponsor	Collaborator
Tourcoing Hospital

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of patients living with HIV who have an inflammatory or autoimmune disease		At the end of the study an average of 18 months
Secondary	Number of patients on immunosuppressive treatment,		At the end of the study an average of 18 months
Secondary	Occurrence of infectious complications		At the end of the study an average of 18 months
Secondary	Number of patients on remission		At the end of the study an average of 18 months
Secondary	Evolution of CD4 and HIV viral load		At the end of the study an average of 18 months